A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leuk
详细信息 查看全文
- 作者：Stacey Zahler1 ; Monica Bhatia2 ; Angela Ricci2 ; Sumith Roy1 ; Erin Morris1 ; Lauren Harrison1 ; Carmella van de Ven1 ; Sandra Fabricatore1 ; Karen Wolownik1 ; Erin Cooney-Qualter3 ; Lee Ann Baxter-Lowe4 ; Paul Luisi1 ; Olga Militano1 ; Morris Kletzel5 ; Mitchell S. Cairo1 ; 6 ; Mitchell_Cairo@nymc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Gemtuzumab ozogamicin ; Reduced-intensity conditioning ; Pediatric AML ; Allogeneic stem cell transplantation ; Immunotherapy
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：22
- 期：4
- 页码：698-704
- 全文大小：521 K
文摘
- m" id="list_ulist0010">
- •
Consolidation GO is well tolerated after RIC alloHSCT.
- •
Optimal consolidation dose of GO after RIC alloHSCT in AML is 9 mg/m2.
- •
MRD may be a risk factor for relapse after RIC alloHSCT in AML.
- •
CD33 maybe a good target to reduce MRD after RIC alloHSCT in AML.
- •
Children with AML in CR1 and CR2 do well after RIC alloHSCT.